HIV+Hep in the News

;

Community groups lose HIV-prevention money as feds redirect dollars to states

by | Oct 1, 2026

“These community-based organizations are on the ground doing the work with the populations that need it,” said Carl Schmid, executive director at the HIV+Hepatitis Policy Institute, a public health nonprofit that tracks policies related to HIV prevention. “Some states may have relationships with some of the existing grantees and may be fine, but others, they may not. And so there’s definitely going to be a lapse of funding.”

read more

Delaware is latest state to enshrine mandatory coverage of PrEP

by | Sep 9, 2026

“DC, Massachusetts, and Delaware have joined a growing number of states and jurisdictions acting to guarantee insurance coverage of highly effective HIV prevention medications known as PrEP without cost-sharing or prior authorization. These laws not only enshrine the coverage requirements into state law, but clarify that the full range of PrEP options, including newer long-acting injectables, must be covered,” HIV+HEP Policy Institute Executive Director Carl Schmid said in a statement applauding the new laws.

read more

Start a prior auth working group, patient advocate says

by | Sep 3, 2026

Carl Schmid, the executive direct of the HIV+Hepatitis Policy Institute, a Washington-based health policy center, talked about the idea at a recent meeting of the National Association of Insurance Commissioners’ NAIC/Consumer Liaison Committee. The new working group should begin by developing consistent definitions and methods that states can use to measure prior authorization activity, Schmid said. Once the working group develops the prior authorization metrics, it should use that information to help states add questions about prior authorization activity to insurance company market conduct examinations, Schmid said.

read more

Stakeholders warn hep C subscription model may not work For GLP-1s

by | Sep 1, 2026

According to the HIV+HEP Policy Institute’s comment letter, another issue is that subscription models that have previously been implemented in Louisiana as well as in Washington state were not as effective as Democratic lawmakers tout them to have been. The HIV patient group notes that while both Louisiana and Washington launched subscription-style drug purchasing programs in 2019 and secured meaningful price reductions through competitive bidding, they both still fell short of their treatment goals.

read more

Search

Pin It on Pinterest

Share This